Shopping Cart
Remove All
Your shopping cart is currently empty
Ebronucimab (Synonyms: AK102, AK 102)
Catalog No. T80608 Copy Product Info
🥰Excellent
Ebronucimab (AK102) is an IgG1 antibody targeting PCSK9 that lowers LDL-C, TC, Non-HDL-C, and ApoB, and raises, HDL-C and Apo A-I for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH).
Ebronucimab
Copy Product Info🥰Excellent
Catalog No. T80608
Synonyms AK102, AK 102
Ebronucimab (AK102) is an IgG1 antibody targeting PCSK9 that lowers LDL-C, TC, Non-HDL-C, and ApoB, and raises, HDL-C and Apo A-I for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH).
Ebronucimab
Cas No. 2304800-90-4
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $232 | - | In Stock | |
| 5 mg | $578 | - | In Stock | |
| 10 mg | $828 | - | In Stock | |
| 25 mg | $1,260 | - | In Stock | |
| 50 mg | $1,680 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:>95.0% (SDS-PAGE); 95.65% (SEC-HPLC)
Appearance:Solution
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Ebronucimab (AK102) is an IgG1 antibody targeting PCSK9 that lowers LDL-C, TC, Non-HDL-C, and ApoB, and raises, HDL-C and Apo A-I for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH). |
| In vivo | In a multi-center randomized controlled trial conducted among Chinese patients with hypercholesterolemia, Ebronucimab, administered at 450 mg every 4 weeks or 150 mg every 2 weeks, significantly reduced serum LDL-C levels over 12 weeks (by approximately 59.13% and 60.43%, respectively), and showed high LDL-C goal achievement rates across different cardiovascular risk categories[1]. |
| Synonyms | AK102, AK 102 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | PCSK9 |
| Molecular Weight | 144.76 kDa |
| Cas No. | 2304800-90-4 |
| Isotype | Human IgG1 lambda2 |
| Recommended Isotype Control |
| Storage | Store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Ebronucimab | purchase Ebronucimab | Ebronucimab cost | order Ebronucimab | Ebronucimab in vivo | Ebronucimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.